References
- Fattovich G, Giustina G, Realdi G, et al. Long-term outcome of hepatitis B e antigen-positive patients with compensated cirrhosis treated with interferon alfa. Hepatology 1997; 26: 1338–42
- Neary MP, Cort S, Bayliss MS, et al. Sustained virologie response is associated with improved health-related quality of life in relapsed chronic hepatitis C patients. Semin Liver Dis 1999; 19(Suppl 1): 77–85
- Han SH, Martin P. Successful antiviral therapy and prognosis in cirrhosis due to hepatitis B. Am J Gastroenterol 1998; 93: 859–60
- Beasley RP, Hwang LY, Lin CC, et al. Hepatocellular carcinoma and hepatitis B virus: a prospective study of 22 070 men in Taiman. Lancet 1981; 2(8256): 1129–33
- Omata M. Treatment of chronic hepatitis B infection. N Engl J Med 1998; 339: 114–5
- Dusheiko G. A pill a day, or two, for hepatitis B? Lancet 1999; 353(9158): 1032–3
- Lau DT, Everhart J, Kleiner DE, et al. Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa. Gastroenterology 1997; 113: 1660–7
- Wong DK, Cheung AM, O'Rourke K, et al. Effect of alphainterferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B: a meta-analysis. Ann Intern Med 1993; 119: 312–23
- DiMarco V, Iacono OL, Camma C, et al. The long-term course of chronic hepatitis B. Hepatology 1999; 30: 257–64
- Lai CL, Chien RN, Leung NW, et al. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998; 339: 61–8
- Dienstag JL, Perillo RP, Schiff ER, et al. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1995; 333: 1657–61
- Chayama K, Suzuki Y, Kobayashi M, et al. Emergence and takeover of YMDD mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy. Hepatology 1998; 27: 1711–6
- Heathcote EJ, Jeffers L, Wright T, et al. Loss of serum HBV DNA and HBeAg and seroconversion following short-term (12 weeks) adefovir dipivoxil therapy in chronic hepatitis B: two placebo-controlled phase II studies. (Abstr) Hepatology 1998; 28: 317A
- Fattovich G, Giustina G, Degos F, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study in 384 patients. Gastroenterology 1997; 112: 463–72
- National Institutes of Health. National Institutes of Health Consensus Development Conference Panel statement: management of hepatitis C. Hepatology 1997; 26 (Suppl 1): 2–10S
- McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa- 2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998; 339: 1485–92
- McHutchison JG, Poynard T. Combination therapy with interferon plus ribavirin for the initial treatment of chronic hepatitis C. Semin Liver Dis 1999; 19(Suppl 1): 57–65
- Davis GL, Esteban-Mur R, Rustgi V, et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med 1998; 339: 1493–9
- Gish RG. Standards of treatment in chronic hepatitis C. Semin Liver Dis 1999; 19(Suppl 1): 35–47
- Davis GL, Nelson DR, Reyes GR. Future options for the management of hepatitis C. Semin Liver Dis 1999; 19(Suppl 1): 103–12
- Interferon plus ribavirin for chronic hepatitis C. Med Lett Drugs Ther 1999; 41(1054): 53–4